Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial
Unique trial tests what emergency doctors should do when screening identifies opioid dependence. More effective at promoting treatment and curbing opioid use than referral and brief advice was, it seems, actually initiating treatment in the form of buprenorphine maintenance.
The Role of Research in Driving Progressive Drug Policy Advocacy: Reconsidering Our Approach
Despite statements from our governments that “evidence-based policy” is a priority, “evidence” is often selectively used, or, as is regularly the case with illicit drug policy, ignored all together
NOT CRIMINALS
Underpinning a health-led approach to drug use
NATIONAL MATOD SUMMIT REPORT
Medication Assisted Treatment for Opioid Dependence (MATOD) in Australia
Public health guidance on prevention and control of blood-borne viruses in prison settings
This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region.
Dr. Robert Newman, Apostle of Methadone Treatment, Dies at 80
Dr. Robert G. Newman at a Manhattan methadone clinic in 2002. He said of heroin addiction, “It’s a medical problem — for which a treatment exists, but for which at the moment a cure does not.”
A more dangerous ‘heroin’: the synthetic opioid overdose crisis in the United States
The Heroin in Transition (HIT) study, funded by the US NIH/NIDA is a 5-year project utilizing multiple disciplinary lenses including economics, epidemiology and anthropology.
Fentanyl in the US heroin supply: A rapidly changing risk environment
The supply of heroin into the US has changed with new source- forms and market strategies. Of particular concern is the rampant and persistent adulteration of heroin with synthetic opioids, most conspicuously the family of fentanyls.
Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency
Overdose deaths in the United States (US) have risen sixfold, paralleled by a rise in the death rate attributed to synthetic opioids, particularly the fentanyls. This paper considers the adaptations some US heroin injectors are making to protect themselves from these risks.
Naloxone-on-Release
Guidelines for naloxone provision upon release from prison and other custodial settings
Share this on: